Replies to post #132892 on Biotech Values

[rwdm]

The patent expiration dates are not in correspondence with the dates that were published for Genentech's biologics:

Product Latest-to-expire product-specific U.S. Patent(s) Year of expiration
Avastin 6,884,879 2017
7,169,901 2019
Rituxan 5,677,180 2014
5,736,137 2015
Herceptin 6,339,142 2019
6,407,213 2019
7,074,404 2019
Lucentis 6,884,879 2017
7,169,901 2019
Xolair 6,329,509 2018
(see http://www.gene.com/gene/ir/downloadDoc.do?id=3841 Page 10).

The biggest discrepancy is in the case of Herceptin: 2019 instead of 2015.